Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty

W.F. Paterson, E. McNeill, D. Young, M.D.C. Donaldson

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Following a successful clinical trial in 1996, the long-acting GnRH analogue goserelin (Zoladex LA 10·8 mg; Astra Zeneca) has been our preferred treatment for central early (CEP) or precocious puberty (CPP). However, some female patients have expressed concern about perceived weight gain during therapy and delay in the onset or resumption of menses on completion of therapy. The primary aim of this study was to investigate these concerns by determining the auxological parameters and timing of menarche or re-menarche in all girls with CEP/CPP who have completed a course of Zoladex LA treatment. The secondary aim was to assess auxological outcome in girls who have attained final height. Our cohort of 46 girls treated with long-acting goserelin was already considerably overweight at the start of therapy and became fatter during treatment. However, adiposity appeared to return to pretreatment levels in the 11 girls followed up to final height. Most of the girls who have attained final height are within or above their expected target range. The relatively long time interval to menarche of 1·5 years after stopping treatment is unexplained but may reflect a residual suppressive effect on the hypothalamo-pituitary axis of this long-acting GnRH analogue. Anticipation of the timing of menarche has proved to be of value in planning when to stop therapy in girls in whom treatment is mainly for practical and/or psychological reasons.
LanguageEnglish
Pages626-634
Number of pages8
JournalClinical Endocrinology
Volume61
Issue number5
DOIs
Publication statusPublished - 2004

Fingerprint

Goserelin
Menarche
Puberty
Precocious Puberty
Therapeutics
Gonadotropin-Releasing Hormone
Menstruation
Adiposity
Weight Gain
Fats
Clinical Trials
Psychology

Keywords

  • goserelin
  • puberty
  • child health
  • statistics
  • clinical endocrinology

Cite this

@article{61539bd1e24f43d28a334cc4bf48d61e,
title = "Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty",
abstract = "Following a successful clinical trial in 1996, the long-acting GnRH analogue goserelin (Zoladex LA 10·8 mg; Astra Zeneca) has been our preferred treatment for central early (CEP) or precocious puberty (CPP). However, some female patients have expressed concern about perceived weight gain during therapy and delay in the onset or resumption of menses on completion of therapy. The primary aim of this study was to investigate these concerns by determining the auxological parameters and timing of menarche or re-menarche in all girls with CEP/CPP who have completed a course of Zoladex LA treatment. The secondary aim was to assess auxological outcome in girls who have attained final height. Our cohort of 46 girls treated with long-acting goserelin was already considerably overweight at the start of therapy and became fatter during treatment. However, adiposity appeared to return to pretreatment levels in the 11 girls followed up to final height. Most of the girls who have attained final height are within or above their expected target range. The relatively long time interval to menarche of 1·5 years after stopping treatment is unexplained but may reflect a residual suppressive effect on the hypothalamo-pituitary axis of this long-acting GnRH analogue. Anticipation of the timing of menarche has proved to be of value in planning when to stop therapy in girls in whom treatment is mainly for practical and/or psychological reasons.",
keywords = "goserelin, puberty, child health, statistics, clinical endocrinology",
author = "W.F. Paterson and E. McNeill and D. Young and M.D.C. Donaldson",
year = "2004",
doi = "10.1111/j.1365-2265.2004.02146.x",
language = "English",
volume = "61",
pages = "626--634",
journal = "Clinical Endocrinology",
issn = "0300-0664",
number = "5",

}

Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. / Paterson, W.F.; McNeill, E.; Young, D.; Donaldson, M.D.C.

In: Clinical Endocrinology, Vol. 61, No. 5, 2004, p. 626-634.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty

AU - Paterson, W.F.

AU - McNeill, E.

AU - Young, D.

AU - Donaldson, M.D.C.

PY - 2004

Y1 - 2004

N2 - Following a successful clinical trial in 1996, the long-acting GnRH analogue goserelin (Zoladex LA 10·8 mg; Astra Zeneca) has been our preferred treatment for central early (CEP) or precocious puberty (CPP). However, some female patients have expressed concern about perceived weight gain during therapy and delay in the onset or resumption of menses on completion of therapy. The primary aim of this study was to investigate these concerns by determining the auxological parameters and timing of menarche or re-menarche in all girls with CEP/CPP who have completed a course of Zoladex LA treatment. The secondary aim was to assess auxological outcome in girls who have attained final height. Our cohort of 46 girls treated with long-acting goserelin was already considerably overweight at the start of therapy and became fatter during treatment. However, adiposity appeared to return to pretreatment levels in the 11 girls followed up to final height. Most of the girls who have attained final height are within or above their expected target range. The relatively long time interval to menarche of 1·5 years after stopping treatment is unexplained but may reflect a residual suppressive effect on the hypothalamo-pituitary axis of this long-acting GnRH analogue. Anticipation of the timing of menarche has proved to be of value in planning when to stop therapy in girls in whom treatment is mainly for practical and/or psychological reasons.

AB - Following a successful clinical trial in 1996, the long-acting GnRH analogue goserelin (Zoladex LA 10·8 mg; Astra Zeneca) has been our preferred treatment for central early (CEP) or precocious puberty (CPP). However, some female patients have expressed concern about perceived weight gain during therapy and delay in the onset or resumption of menses on completion of therapy. The primary aim of this study was to investigate these concerns by determining the auxological parameters and timing of menarche or re-menarche in all girls with CEP/CPP who have completed a course of Zoladex LA treatment. The secondary aim was to assess auxological outcome in girls who have attained final height. Our cohort of 46 girls treated with long-acting goserelin was already considerably overweight at the start of therapy and became fatter during treatment. However, adiposity appeared to return to pretreatment levels in the 11 girls followed up to final height. Most of the girls who have attained final height are within or above their expected target range. The relatively long time interval to menarche of 1·5 years after stopping treatment is unexplained but may reflect a residual suppressive effect on the hypothalamo-pituitary axis of this long-acting GnRH analogue. Anticipation of the timing of menarche has proved to be of value in planning when to stop therapy in girls in whom treatment is mainly for practical and/or psychological reasons.

KW - goserelin

KW - puberty

KW - child health

KW - statistics

KW - clinical endocrinology

UR - http://dx.doi.org/10.1111/j.1365-2265.2004.02146.x

U2 - 10.1111/j.1365-2265.2004.02146.x

DO - 10.1111/j.1365-2265.2004.02146.x

M3 - Article

VL - 61

SP - 626

EP - 634

JO - Clinical Endocrinology

T2 - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 5

ER -